The Latest
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
In a cash-and-stock deal, Lyell Immunopharma acquired from Innovative Cellular Therapeutics rights to a cell therapy in early-stage testing for metastatic colon cancer.
Updated 7 hours ago -
Tasos Katopodis via Getty Images
FDA to remove safety warnings on hormonal menopause therapy
The decision, issued without the input of an official advisory committee, revises long-held labeling on the drugs cautioning the risk of cancer and heart disease.
-
Alamy
Merck showcases data suggesting PCSK9 pill might rival cholesterol-lowering shots
Merck’s pill, which could be the first oral PCSK9 drug to get to market, displayed similar effects on lipid levels as injectable medicines from Amgen and Regeneron.
Updated Nov. 10, 2025 -
Getty Images
Lilly picks up an eye gene therapy in deal with MeiraGTx
The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment for an ultra-rare form of childhood blindness.
-
Getty Images
News roundupPatient dies in Intellia trial; FDA awards 6 more ‘national priority’ vouchers
The death of a study volunteer further complicates the path forward for Intellia’s on-hold rare disease treatment. Elsewhere, Gilead reported a setback and J&J netted a first-of-its-kind approval.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech’s M&A outlook is uncertain. Track the deals that are happening here.
Pfizer’s winning bid for Metsera brought the deal’s total value to $10 billion, tying it for the third-largest biopharmaceutical company acquisition this year.
Updated Nov. 10, 2025 -
Andrew Harnik via Getty Images
Trump administrationNovo, Lilly cut deal with Trump to lower prices of obesity drugs
The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.
Updated Nov. 7, 2025 -
deliormanli via Getty Images
Emerging biotechCorporate venture firms stepped in for drug startups during biotech funding pullback
According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year.
-
Robert Way via Getty Images
Obesity drugsAstraZeneca exercises option to buy an obesity startup
The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight loss-focused startup it helped launch last year.
-
Permission granted by eClinical Solutions
Pharma’s clinical trial diversity push faces a new threat
Skyrocketing healthcare costs could deliver another blow to the industry’s ongoing quest to boost representation in R&D.
-
Andrew Harnik/ via Getty Images
CMS to launch model to lower Medicaid drug spending
Under the model, set to start next year, the CMS will negotiate lower prices for Medicaid programs linked to those paid in select other countries.
-
Maddie Meyer via Getty Images
VaccinesModerna leans on cost cuts, pipeline as vaccine sales dip
Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to break even financially in 2028 with the help of more disciplined spending.
-
Adeline Kon/BioPharma Dive
Deep Dive // Emerging biotechBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Including Evommune’s IPO Wednesday, only 10 biotechs have gone public in 2025, less than half the nearly two dozen that had priced offerings by this time last year.
Updated Nov. 6, 2025 -
Getty Images
J&J brain drug acquired in $14.6B buyout cleared for broader use
Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s key to achieving the $5 billion in annualized sales the company expects.
-
Getty Images
Obesity drugsFTC signals scrutiny of Novo’s bid for Metsera
Without taking a firm position, the antitrust agency said Novo’s two-step deal structure may illegally sidestep requirements for a premerger review.
-
Getty Images
IPO windowEvommune nabs $150M in IPO amid federal shutdown
The immune drugmaker is the second biotech, along with MapLight Therapeutics, to recently use a workaround in U.S. securities law to price an offering during the shutdown.
-
Permission granted by Biohaven Ltd.
Knocked back by the FDA, Biohaven turns to major cost cuts
The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.
-
Permission granted by HI-Bio
Emerging biotechBraveheart secures $185M to advance challenger to Bristol Myers heart drug
The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of similar treatments for hypertrophic cardiomyopathy.
-
Scott Olson via Getty Images
Novo narrows sales outlook as GLP-1 price cuts loom
Ahead of a reported White House deal meant to lower the cost of obesity drugs like Wegovy, Novo said “intensifying competition and pricing pressure” led it to lower its yearly sales projections.
-
Getty Images
News roundup
Soleno slumps despite sales uptick; Madrigal’s MASH drug continues ascent
Soleno shares fell double digits amid questions about the growth trajectory of its Prader-Willi drug. Elsewhere, a cancer medicine at the center of a $1.9 billion buyout fell short in a key trial.
-
Jacob Bell/BioPharma Dive
Sarepta Duchenne drugs come up short in confirmatory test
Still, CEO Doug Ingram claimed removing the two drugs, Vyondys 53 and Amondys 45, from market would make “little sense” and that the evidence accrued to date makes a strong case for full approval.
-
Courtesy of UniQure
UniQure dives after FDA’s ‘very surprising’ reversal on Huntington’s gene therapy
The FDA’s abrupt shift on UniQure’s treatment reflects an agency that, under current leadership, is as unpredictable as it's been in years, some analysts said.
-
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive // Emerging biotechBiotech startups are built on venture capital. Track funding rounds here.
Braveheart Bio’s $185 million funding this week was among the top 10 largest Series A rounds this year among the investment firms tracked by BioPharma Dive.
Updated Nov. 7, 2025 -
Courtesy of Novo Nordisk
Obesity drugsMetsera again chooses Novo as bidding war with Pfizer intensifies
The obesity drug developer has declared a new proposal from Novo “superior” to Pfizer’s original bid as well as an updated offer revealed Tuesday.
-
Getty Images
Vertex’s new pain, blood disorder drugs miss Wall Street expectations
While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.
